Pantoprazol Farmalider (Pantoprazole)

Pantoprazole works by selectively and irreversibly inhibiting the H+/K+‑ATPase enzyme (the gastric proton pump) on the secretory surface of parietal cells. This blocks the final step of acid secretion, leading to a sustained increase in gastric pH and a reduction in overall gastric acidity.

The dose of Pantoprazol Farmalider is determined by the prescribing clinician based on the specific indication, severity of disease and patient factors. The prescriber sets the appropriate strength, frequency and duration of therapy according to current clinical guidelines.

Pantoprazole is classified as pregnancy category B in many regions, indicating no evidence of risk in animal studies but limited human data. It should be used during pregnancy or lactation only if clearly needed after a careful risk‑benefit assessment by the healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Pantoprazole belongs to the proton pump inhibitor class, which provides more potent and longer‑lasting acid suppression than H2‑receptor antagonists such as ranitidine. Compared with other PPIs, pantoprazole has a lower potential for drug‑drug interactions mediated by CYP2C19, making it a suitable option for patients on multiple medications.

Store Pantoprazol Farmalider tablets at temperatures below 25 °C in the original container, protecting them from moisture and direct sunlight. Do not expose the tablets to excessive heat or humidity, and keep them out of reach of children.

Pantoprazol Farmalider is supplied as oral tablets that are taken with water. For optimal absorption, it is usually recommended to swallow the tablet whole, preferably before a meal, although specific timing should follow the prescribing clinician’s instructions.

Serious risks, though uncommon, include severe allergic reactions (anaphylaxis), Clostridioides difficile‑associated diarrhoea, acute interstitial nephritis, hypomagnesemia and an increased risk of bone fractures with long‑term use. Patients should be monitored for these events and advised to seek immediate medical care if they occur.

Pantoprazol Farmalider is contraindicated in patients with known hypersensitivity to pantoprazole or any other component of the formulation. Caution is also advised for individuals with severe liver disease, those taking certain interacting medications such as clopidogrel, and patients for whom acid suppression is not indicated.